Imagine Institute of Genetic Diseases

What Imagine Institute of Genetic Diseases does

Imagine Institute of Genetic Diseases (Institut Imagine) is a non-profit scientific cooperation foundation established in Paris by decree on June 15, 2007, and co-located with Hôpital Necker-Enfants malades. The institute operates a unique care-research continuum, integrating clinical care, fundamental research, and translational applications across human genetics, immunology, developmental biology, gene therapy, and cellular therapies. Approximately 1,000 physicians, researchers, and engineers work within research teams, core facilities (genomics, proteomics, imaging, single-cell analysis), and the Imagine Clinical Research Platform; the institute has conducted 580 clinical trials and houses programs such as the DREPAGLOBE gene therapy vector for hemoglobinopathies and the TYRA-300 FGFR3 inhibitor collaboration with Tyra Biosciences for skeletal dysplasias.

The institute is governed by six founding institutional members — AP-HP, INSERM, Université Paris Cité, Ville de Paris, Fondation des Hôpitaux, and AFM Téléthon — and holds IHU (University Hospital Institute) certification from the ANR and the Institut Carnot label from the French Ministry of Research. Revenue is generated through a diversified mix of government research grants (national and European Horizon programs), institutional funding from founding members, individual and major donor philanthropy, corporate sponsorships, industry licensing, and technology transfer via a dedicated Innovation and Technology Transfer Department. Patient care is delivered through the French public healthcare system at Hôpital Necker-Enfants malades.

Distribution of research outputs occurs through scientific publications, international collaborations (InFlaMe, ATRACTion, EU-IFNp, Cancer Grand Challenges), and ecosystem programs including the Medtech Generator & Accelerator (with Institut du Cerveau and Institut de la Vision), the BioLaunchpad bioentrepreneurs program, an International Doctoral Program, and Monday Seminars. Patient and family segments access care and clinical trial participation; researcher and clinician segments access collaboration, training, and technology transfer opportunities. Leadership includes Executive Director Laure Boquet, Deputy Director Guillaume Huart, and senior scientists such as Jean-Laurent Casanova (2025 Novo Nordisk Prize).

Name

Imagine Institute of Genetic Diseases

Legal name

Imagine Institute – Institute for Genetic Diseases

Website

https://institutimagine.org

Company type

Private

Founded year

2007

Operating status

Operating

Short description

Imagine Institute of Genetic Diseases is a Paris-based non-profit scientific foundation co-located with Hôpital Necker-Enfants malades, conducting integrated research and clinical care in human genetics, immunology, gene therapy, and rare genetic diseases for patients, families, and the global research community.

Ownership category

akta.pro rank

Product category

Genetic Disease Research and Clinical Care

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

AAV Vector Gene Therapy Developers (HLAAACAA), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Genetic disease research
• Clinical research services
• Rare disease diagnostics
• Gene therapy research
• Medical research institute

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Research Funding and Grants: The institute operates as a public-private partnership funded through government research grants, institutional funding from founding members (INSERM, AP-HP, Université Paris Cité), private donations, corporate sponsorships, and competitive research grants from national and European funding bodies.
2. Donations and Philanthropy: Individual donations, major donor programs, legacy gifts, and corporate partnerships support the institute's mission. Tax-deductible donation options are offered to donors.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Imagine Institute of Genetic Diseases is a non-profit scientific foundation that conducts fundamental and translational research on genetic diseases, delivers specialized clinical care through its co-location with Hôpital Necker-Enfants Malades in Paris, and operates training, technology-transfer, and acceleration programs. It combines a care-research continuum with core facilities (genomics, proteomics, imaging, single-cell analysis) and runs over 580 clinical trials targeting rare and common genetic conditions.

Product overview

Imagine Institute of Genetic Diseases is a research and healthcare institute focused on understanding and treating genetic diseases. The organization operates as a unified research ecosystem combining integrated care and research programs through its Imagine Clinical Research Platform, supported by research teams, core facilities, and associated laboratories. The institute offers technology transfer and innovation services including the BioLaunchpad bioentrepreneurship program and the Medtech Generator & Accelerator (MGA) program developed in partnership with Institut du Cerveau and Institut de la Vision. Educational offerings include an International Doctoral Program and Monday Seminars. The institute maintains clinical care operations at Hôpital Necker-Enfants Malades, providing a unique care-research continuum for patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Care for Genetic Diseases at Hôpital Necker-Enfants Malades
• Imagine Clinical Research Platform
• Medtech Generator & Accelerator (MGA)
• BioLaunchpad Bioentrepreneurs Program
• Innovation and Technology Transfer Services

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered major, supporting and founding.

• Cancer Grand ChallengesmajorStrategic or Co-development Partner · 10 March 2025International cancer research funding initiative supporting Dr Paul Bastard's ATLAS team at the institute.
• InFlaMe Consortium PartnersmajorStrategic or Co-development Partner · 1 January 2025International consortium including Fondazione IRCCS Policlinico San Matteo (Italy), Fondazione INGM (Italy), Universita Degli Studi di Firenze (Italy), Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (Italy), Institut Pasteur (France), Medizinische Universitaet Wien (Austria), Masarykova Univerzita (Czechia), Asociacion Centro De Investigacion Cooperativa En Biociencias (Spain) for flavivirus research funded by Horizon Europe.
• Tyra BiosciencessupportingTechnology or Integration · 1 January 2024Collaboration on TYRA-300 FGFR3 selective inhibitor for treatment of achondroplasia and related skeletal dysplasias. The company synthesized the therapeutic molecule evaluated in institute research.
• Medtech Generator & Accelerator ConsortiummajorStrategic or Co-development Partner · 1 September 2021Joint program with Institut du Cerveau and Institut de la Vision, coordinated by iPEPS Healthtech Hub incubator, to accelerate medtech startups in neuroscience and genetic/rare diseases. Supported by French Future Investment Program (BpiFrance).
• ATRACTion Project ConsortiummajorStrategic or Co-development Partner · 1 January 202111 academic and industrial partners including INSERM, APHP, INRA, CEA, University of Paris, Sanofi, and Ariana Pharma focused on primary immunodeficiencies using single-cell analysis and artificial intelligence.
• Assistance Publique-Hôpitaux de Paris (APHP)foundingStrategic or Co-development Partner · 15 June 2007Founding institutional partner providing hospital facilities at Hôpital Necker-Enfants malades and clinical care infrastructure. The institute is co-located with this major European hospital system enabling integrated care-research continuum.
• INSERMfoundingStrategic or Co-development Partner · 15 June 2007French National Institute of Health and Medical Research as founding institutional member providing research framework and scientific oversight.
• Université Paris CitéfoundingStrategic or Co-development Partner · 15 June 2007Academic founding partner providing university affiliation, doctoral programs, and academic research integration.
• Ville de ParisfoundingStrategic or Co-development Partner · 15 June 2007City of Paris as founding institutional member supporting the institute's mission.
• Fondation des HôpitauxfoundingStrategic or Co-development Partner · 15 June 2007Hospital Foundation as founding partner supporting healthcare and research mission.
• AFM TéléthonfoundingStrategic or Co-development Partner · 15 June 2007French Muscular Dystrophy Association (Association Française contre les Myopathies) as founding partner providing patient advocacy connection and research support.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Institut Curie: French non-profit foundation combining a research center with a hospital, focused on cancer and genetic diseases. Its integrated care-research model and rare disease programs are highly comparable to Imagine's structure at Hôpital Necker-Enfants malades.
• Institut Pasteur: Paris-based non-profit research foundation with a similar integrated model of fundamental research, clinical/medical activity and translation, including strong human genetics, immunology and infectious disease programs comparable to Imagine's portfolio.
• Boston Children's Hospital – Gene Therapy Program: Leading US pediatric hospital running a dedicated gene therapy program targeting monogenic and rare diseases, including sickle cell and other hematologic disorders—overlapping substantially with Imagine's DREPAGLOBE and rare-disease pipeline.
• Children's Hospital of Philadelphia (CHOP) Research Institute: Major US pediatric research institute with deep programs in rare genetic diseases, gene therapy and clinical trials for pediatric populations—directly comparable to Imagine's pediatric rare-disease focus at Hôpital Necker-Enfants malades.
• Berlin Institute of Health at Charité (BIH): German translational research institute embedded in a large university hospital (Charité) with a model that combines fundamental research, clinical care and translation—structurally very similar to Imagine's Necker co-location.
• Wellcome Sanger Institute: UK genomic research institute conducting large-scale genetic and genomic research with strong translational pipelines. Highly comparable to Imagine's human genetics, single-cell and rare disease research focus.

Broad incumbents

• Broad Institute of MIT and Harvard: Major US genomics and biomedical research institute with deep capabilities in human genetics, gene therapy and clinical translation. Comparable in scientific scope and translational ambition to Imagine, though operating at larger scale.
• The Francis Crick Institute: Large UK biomedical discovery institute operating as a public-private partnership with multiple university and charity founders. Comparable in scale (~1,000+ scientists), translational orientation and breadth of biomedical research programs.

Regional players

• Garvan Institute of Medical Research: Australian non-profit medical research institute focused on genomics, immunology and rare diseases with affiliated clinical activities. Comparable in mission and translational orientation, though geographically distinct from Imagine.

Emerging players

• Helmholtz Zentrum München – Institute of Human Genetics: German publicly funded research institute with strong human genetics, rare disease and translational programs. Comparable as a European non-academic research center in the same disease space as Imagine.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xbsky.app/profile/institutimagine.bsky.social
• YouTubeyoutube.com/channel/UCiobYLl7VtngPGYbb8jQGmg
• Facebookfacebook.com/InstitutImagine
• LinkedInlinkedin.com/company/imagine-institute-of-genetic-diseases
• Instagraminstagram.com/institut_imagine

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imagine Institute of Genetic Diseases